Subproject PIs
Tumor Profiling and Preclinical Models
![Lauri Aaltonen](https://ican.fi/wp-content/uploads/2023/10/ican-lauri-aaltonen.jpg)
Lauri Aaltonen
iCAN-LUMI: Improved management of uterine leiomyoma
![Vincenzo Cerullo](https://ican.fi/wp-content/uploads/2023/10/ican-vincenzo-cerullo.jpg)
Vincenzo Cerullo
iCAN-COMPORG: Towards clinically relevant assays and translational utility
![Anniina Färkkilä](https://ican.fi/wp-content/uploads/2023/10/ican-anniina-farkkila.jpg)
Anniina Färkkilä
iCAN-OVCA: Single-cell spatial immunogenomic profiling for precision oncology in ovarian cancer
![Ilkka Ilonen](https://ican.fi/wp-content/uploads/2023/10/ican-ilkka-ilonen.jpg)
Ilkka Ilonen
iCAN-LUNG: Thoracic oncology: new frontiers for personalized immuno-oncologic therapy
![Minna Koskenvuo](https://ican.fi/wp-content/uploads/2023/10/ican-minna-koskenvuo.jpg)
Minna Koskenvuo
iCAN-PEDI: Life-long longitudinal study of childhood cancer patients for personalized health
![Pirjo Laakkonen](https://ican.fi/wp-content/uploads/2023/10/ican-pirjo-laakkonen.jpg)
Pirjo Laakkonen
iCAN-BRAIN: Translating the dialogue between tumor stroma and cancer cells into therapeutic opportunities
![Outi Monni](https://ican.fi/wp-content/uploads/2023/10/ican-outi-monni.jpg)
Outi Monni
iCAN-RARE: Advancing ex vivo drug testing and precision oncology of rare tumors
![Satu Mustjoki](https://ican.fi/wp-content/uploads/2023/10/ican-satu-mustjoki02.jpg)
Satu Mustjoki
iCAN-IMMPROF: Functional immunological profiling: combination of cellular therapies and immune modulating drugs in primary patient samples
Pauli Puolakkainen
iCAN-GC: Role of the tumor subtype and microenvironment in the growth and therapy resistance of gastric cancer
Tuula Salo
iCAN-ORACAN: Personalized cancer medicine assays for oral cancers
Hanna Seppänen
iCAN-PaCa: Pancreatic cancer – New developments in diagnostics, biology and treatment
Sakari Vanharanta
iCAN-REGU: Integrative regulatory genome analysis for precision cancer medicine
Markku Varjosalo
iCAN-DETECT: Decoding tumor signatures through proteomics technology
Towards clinical trials
Andrea Ganna
iCAN-EDECA: Feasibility of high-performance methylation sequencing (EM-seq) of cell-free DNA for early cancer detection from routinely collected biobank samples
Caroline Heckman
iCAN-HEMADRUG2: Understanding and targeting non-mutational drug resistance in blood cancer
Sirpa Leppä
iCAN-LBTRIAL: Liquid biopsy–guided therapy in lymphomas and advanced solid tumors
Nina Mars
iCAN-GERPROG-BREAST: Germline genetic risk in prognosis of solid malignancies
Päivi Ojala
iCAN-CART: Deep profiling to understand and improve Chimeric Antigen Receptor (CAR) T-cell therapy for haematological cancers
Toni Seppälä
iCAN-PANORG-HEMOPRO: Heavy molecular profiling for clinical decision-making in advanced colorectal cancer
Omics approaches and data platform
Tero Aittokallio
iCAN-MULTIDRUG: Platform for identification of multi-drug combinations targeting tumor-stromal cell interactions in solid tumors at single-cell resolution
Andrew Erickson
iCAN-URO: Spatial Characterization of Cancer Biologies
Johan Lundin
iCAN-AIDX: Artificial intelligence deep learning system for personalized patient predictions
Mikko Myllymäki
iCAN-CHIP: The spectrum of clonal hematopoiesis and therapy outcomes in cancer
Lassi Paavolainen
iCAN-DIP: AI-driven deep image-based profiling of pan-cancer tumor microenvironment
Esa Pitkänen
iCAN-DPM: Data Platform Management including MuMaLe, DB, and MTB
Kimmo Porkka
iCAN-SHARE: Enabling global cancer data sharing networks for federated learning